{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:16:40Z","timestamp":1747167400232,"version":"3.40.5"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.medcli.2023.11.019","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T02:01:25Z","timestamp":1705111285000},"page":"485-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inmunoterapia en el mieloma m\u00faltiple"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-3656","authenticated-orcid":false,"given":"Pedro","family":"Asensi Cant\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Arnao Herraiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia Comos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2023.11.019_bib0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.medcli.2023.11.019_bib0310","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leuk."},{"key":"10.1016\/j.medcli.2023.11.019_bib0315","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0320","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0325","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0335","article-title":"LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"4","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0345","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"Phase AI. First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen\u00d7CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0350","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1538-7445.AM2023-CT013","article-title":"Safety and efficacy from the phase 1\/2 first-in-human study of REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with relapsed\/refractory multiple myeloma","volume":"83","author":"Suvannasankha","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.medcli.2023.11.019_bib0355","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2023.11.019_bib0360","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2023.11.019_bib0365","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2023.11.019_bib0370","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0375","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring Responses after 1-Year Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0380","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0385","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41571-023-00735-4","article-title":"GPRC5D as a novel immunotherapeutic target in multiple myeloma","volume":"20","author":"Nath","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0390","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec)+talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2023.11.019_bib0395","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal)+daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0400","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.medcli.2023.11.019_bib0405","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0410","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2023.11.019_bib0415","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134319","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study","volume":"136","author":"Raje","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0420","article-title":"Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0425","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0430","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-10824-3","article-title":"Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients","volume":"23","author":"Sanoyan","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.medcli.2023.11.019_bib0440","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2023.11.019_bib0445","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0450","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146069","article-title":"Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis","volume":"138","author":"Jakubowiak","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0455","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0460","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): A single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0465","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0470","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Suppl","key":"10.1016\/j.medcli.2023.11.019_bib0475","first-page":"8504-8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2023.11.019_bib0480","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0485","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medcli.2023.11.019_bib0490","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0495","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8033","article-title":"Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1","volume":"41","author":"Van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0500","doi-asserted-by":"crossref","first-page":"477.e1","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.medcli.2023.11.019_bib0505","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2023.11.019_bib0510","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.medcli.2023.11.019_bib0515","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T-cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0520","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2023.11.019_bib0525","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1080\/10428194.2023.2240920","article-title":"Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma","volume":"64","author":"Duvalyan","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2023.11.019_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medcli.2023.11.019_bib0535","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.clml.2020.04.020","article-title":"Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra","volume":"20","author":"Jatiani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.medcli.2023.11.019_bib0540","first-page":"2443","article-title":"How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0545","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0555","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA\/EBMT Consensus Grading and Best Practice Recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0560","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0565","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: A pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2023.11.019_bib0570","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2023.11.019_bib0575","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1182\/blood-2022-165650","article-title":"Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Hoeynck","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0580","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.11.019_bib0585","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2023.11.019_bib0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.medcli.2023.11.019_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.medcli.2023.11.019_bib0600","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775323007534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775323007534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T12:56:19Z","timestamp":1716296179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775323007534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0025775323007534"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2023.11.019","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inmunoterapia en el mieloma m\u00faltiple","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2023.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}